MAPT and Alzheimer disease: There are results that hyperglycemia or impaired insulin signaling may be directly involved with the pathophysiology of AD (e.g., tau cleavage and apoptosis) and many reports support that metabolic dysfunction exacerbate the progression of AD in patients [35].